TELIX PHARMACEUTICALS LTD
TLXNASDAQUS Equity
$968.83▼ $36.04 (−3.72%)
Simulated price1h—
24h▼ 3.7%
7d—
14d—
30d—
1y—
🏦Market Cap
$289.25B
Large Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
49
Weak
No chart data available for TLX.
Trading Snapshot
- Day Range
- $963.60 – $986.09
- 52-Week Range
- $6.28 – $16.98
- Volume
- $3.47B
- Avg Volume
- $3.31B
- Shares Outstanding
- —
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $50.75B
- Last Q Revenue
- $12.04B
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own TLX
- ✓High-growth profile — revenue up +34.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 52% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$50.75B▲ +30.8% YoY
Gross Margin (TTM)
52.3%▲ +0.5% YoY
Operating Income (TTM)
$18.52B▲ +30.8% YoY
Free Cash Flow (TTM)
$5.84B▲ +30.8% YoY
About TELIX PHARMACEUTICALS LTD
A company profile for TELIX PHARMACEUTICALS LTD isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
49/100
Analyst Price Target
ⓘAverage Target
$1,138.42
▲ +17.5% Upside
High Target$1,388.19
Low Target$922.59
Based on 34 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
TELIX PHARMACEUTICALS LTD tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift TLX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
TELIX PHARMACEUTICALS LTD announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.